David Rubinstein, Ph.D., Senior Vice President, Business Development

April 9 | 1:30pm | Salone dei Cavalieri, Section 3&4

New York, NY


MeiraGTx is a clinical-stage, fully integrated, gene therapy company with six programs in clinical development across ocular, neurodegenerative and salivary gland conditions. MeiraGTx has core in-house capabilities in viral vector design and optimization, as well as in-house end-to-end cGMP manufacturing facilities. MeiraGTx has developed a proprietary and transformative riboswitch-based gene regulation technology, which allows precise dose-responsive control of gene expression with oral small molecule inducers. This technology can be applied to control the expression of any transgene, including in gene therapy gene editing and cell therapy. MeiraGTx has also developed an extensive array of proprietary constitutive and cell-specific synthetic promoters, by combining rational, high-throughput, and AI/ML approaches for promoter screening and design.

By using this website you agree to accept our Privacy Policy and Terms & Conditions